Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cardinal Health $1.15 billion notes offering
The investment-grade notes are due 2029 and 2034
Prime Medicine $161 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Market
Cigna $4.5 billion senior notes offering
The senior notes are due 2029, 2031, 2034 and 2054
Novo Nordisk class certification victory
The district court denied plaintiffs’ motion for class certification in its entirety
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064